The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...
Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...
Machine learning is driving efforts to classify MS into distinct subtypes that may predict disease course, but two experts debate whether this will advance patient care.
A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting ...
The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.
The Merck KGaA collaborated with actress and patient advocate Selma Blair for the I’m Ready campaign. When EMD Serono embarked on a campaign to empower patients living with relapsing multiple ...
India], March 11: Merck Foundation, the philanthropic arm of Merck KGaA Germany, together with First Ladies of Africa and ...
The US approval for relapsing/remitting and secondary progressive MS comes a couple of years after Merck won European approval for Mavenclad (cladribine), and several years after the first ...
This constitutes real proof of efficacy in MS." MS often starts with an acute ... the French National Research Agency, Biogen, Merck, Novartis, Roche, Sanofi, France SEP, and the EDMUS Foundation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback